Stock Analysis

Global Value Stocks Trading At Estimated Discounts In May 2025

TSE:4568
Source: Shutterstock

In May 2025, global markets are navigating a turbulent landscape marked by renewed tariff threats and volatility in the Treasury market, which have contributed to declines in major stock indexes. Amid these challenges, investors may find opportunities in undervalued stocks that offer potential value based on their fundamentals and current market conditions.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Pansoft (SZSE:300996)CN¥14.19CN¥28.3249.9%
Sanil Electric (KOSE:A062040)₩66100.00₩130358.7449.3%
Laboratorios Farmaceuticos Rovi (BME:ROVI)€52.35€104.4749.9%
Sahara International Petrochemical (SASE:2310)SAR18.80SAR37.3449.7%
H.U. Group Holdings (TSE:4544)¥3056.00¥6024.9849.3%
Dive (TSE:151A)¥921.00¥1821.2049.4%
BalnibarbiLtd (TSE:3418)¥1160.00¥2296.5849.5%
Cosmax (KOSE:A192820)₩202500.00₩404786.4250%
J&T Global Express (SEHK:1519)HK$6.65HK$13.2149.7%
Northern Data (DB:NB2)€25.02€49.5349.5%

Click here to see the full list of 516 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Tsinghua Tongfang (SHSE:600100)

Overview: Tsinghua Tongfang Co., Ltd. operates in digital information, civil nuclear technology, energy conservation and environmental protection, and technology and finance sectors with a market cap of CN¥24.02 billion.

Operations: The company's revenue segments include digital information, civil nuclear technology, energy conservation and environmental protection, and technology and finance businesses.

Estimated Discount To Fair Value: 44.4%

Tsinghua Tongfang is trading at a significant discount, with its current price of CN¥7.23 well below the estimated fair value of CN¥13.01, indicating potential undervaluation based on cash flows. Despite recent financial challenges, including a net loss of CNY 287.6 million in Q1 2025, earnings are forecast to grow substantially at 93.8% annually over the next three years, outpacing both industry peers and the broader Chinese market growth rates.

SHSE:600100 Discounted Cash Flow as at May 2025
SHSE:600100 Discounted Cash Flow as at May 2025

Jiangsu Shentong Valve (SZSE:002438)

Overview: Jiangsu Shentong Valve Co., Ltd. is engaged in the research, development, production, and sale of special valves both in China and internationally, with a market cap of CN¥5.79 billion.

Operations: The company generates revenue from the research, development, production, and sale of special valves within China and on an international scale.

Estimated Discount To Fair Value: 14.3%

Jiangsu Shentong Valve is trading at CN¥11.87, below its estimated fair value of CN¥13.85, suggesting it may be undervalued based on cash flows. The company reported Q1 2025 earnings with a net income increase to CN¥89.5 million from the previous year’s CN¥83.69 million, and revenue growth outpacing the market at 20.4% annually. Analysts expect significant annual profit growth of 24.8%, supported by a reliable dividend payout and strong earnings forecasts relative to peers.

SZSE:002438 Discounted Cash Flow as at May 2025
SZSE:002438 Discounted Cash Flow as at May 2025

Daiichi Sankyo Company (TSE:4568)

Overview: Daiichi Sankyo Company, Limited is a pharmaceutical manufacturer and seller operating in Japan, North America, Europe, and internationally with a market cap of ¥7.11 trillion.

Operations: The company's pharmaceutical operation generates revenue of ¥1.89 trillion.

Estimated Discount To Fair Value: 48.6%

Daiichi Sankyo, trading at ¥3,945, is valued below its estimated fair value of ¥7,679.39 according to cash flow analysis. The company's earnings grew by 47.3% last year and are forecasted to grow annually by 12.88%. Despite a dividend yield of 1.98% not being well-covered by free cash flows, the company has initiated share buybacks worth ¥200 billion to enhance shareholder value amidst ongoing legal challenges and promising oncology developments like ENHERTU's clinical success.

TSE:4568 Discounted Cash Flow as at May 2025
TSE:4568 Discounted Cash Flow as at May 2025

Make It Happen

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com